Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2016-06-23 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2016-06-23 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-06-23 English
8-K 2016 SH MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 22, 2016, reporting the submission of matters to a vote of security holders at the 2016 Annual Meeting of Stockholders. It details the voting results on four proposals including election of directors, executive compensation advisory vote, reverse stock split amendment, and appointment of the independent auditor. The content is focused on official results from shareholder votes at a general meeting. The document length is 4196 characters, which is relatively short but contains detailed voting results rather than just an announcement of a report. The key section is 'Item 5.07. Submission of Matters to a Vote of Security Holders,' which matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the correct classification is DVA with high confidence.
2016-06-23 English
S-8 JUNE 2016
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity compensation plans. It includes details about the securities to be registered, the equity compensation plan, indemnification provisions, and references to other SEC filings. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a capital market filing related to securities registration for employee stock plans, which falls under the category of Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2016-06-23 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-06-07 English
424B3 PROSPECTUS JUNE 2016
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) under the Securities Act of 1933. It relates to the resale or disposition of shares by selling stockholders and includes detailed information about the offering, risk factors, use of proceeds, selling stockholders, and plan of distribution. The document is not a financial report, earnings release, or management discussion but a registration prospectus for securities offering. This type of document corresponds to a Capital/Financing Update as it provides information about the company's securities offering and related capital raising activities.
2016-06-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.